Eurofins signs an exclusive agreement to acquire the Biomnis Group
Biomnis is one of the main independent specialty/esoteric diagnostic testing service providers in France and Ireland. It is one of the largest independent laboratories in Europe focusing on specialty diagnostic testing, with a strong reputation in many areas including infectious diseases, supported by its renowned competence in molecular biology and cytogenetics. Biomnis has 2 main sites in France (Lyon and Paris) and 1 site in Ireland. In addition, it owns 26 medical biology sites across France that run less complex tests, and are also channels for the specialty diagnostic tests which are then sent on to the laboratories in Paris or Lyon. The company is also active in clinical trials for the pharmaceutical industry, and in forensic testing. Biomnis serves mainly institutional clients including hospitals, pharmaceutical companies and a large number of other third party medical biology laboratories which outsource the more complex tests to Biomnis. Given the ongoing consolidation in the clinical testing sector in Europe, and specifically in France, the company is well-positioned to leverage and strengthen its footprint in the specialty diagnostic testing sector.
Should the contemplated transaction come to closing, the addition of Biomnis to the Eurofins network would strengthen the Group's pharmaceutical and genomic service offering, and consolidate its growing presence in the specialty diagnostic testing sector, following the acquisition of ViraCor, Boston Heart and Diatherix in the US. Furthermore, Biomnis should provide the Group a strong platform in Europe on which to deploy its technical know-how in specialty clinical diagnostic testing, and strengthen its position in this sector in France, in addition to the acquisition of BioAccess. Eurofins' renowned capabilities in genomic testing, and its international presence, should support Biomnis in developing its portfolio of tests and services, as well as consolidate their client reach.
Most read news
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.